Document is current
Any future updates will be listed below
-
Authors
Alsaloum, Matthew https://orcid.org/0000-0002-9832-0138
Dib-Hajj, Sulayman D. https://orcid.org/0000-0002-4137-1655
Page, Dana A.
Ruben, Peter C.
Krainer, Adrian R. https://orcid.org/0000-0001-9024-9501
Waxman, Stephen G. https://orcid.org/0000-0001-5718-7177
- License Information
-
More Information
Article History
Accepted: 21 November 2024
First Online: 3 February 2025
Competing interests
: S.D.D.-H has served as an adviser or consultant to Ionis Pharmaceuticals, Alnylam Pharmaceuticals and Q-State Biosciences. A.R.K. is a co-founder, director and shareholder of Stoke Therapeutics; a member of the SABs of Skyhawk Therapeutics, Envisagenics and Autoimmunity BioSolutions; and a consultant for Biogen, SEED Therapeutics, Crucible Therapeutics, Cajal Neuroscience, Collage Bio and Solstar Pharma. S.G.W. serves on the Scientific Advisory Board and holds stock in Navega Therapeutics and SiteOne Therapeutics; has served as an adviser or consultant to Medtronic, Amgen, Biogen, Glaxo SmithKline, Eli Lilly, Third Rock Therapeutics, OliPass Biotherapeutics, Sangamo Pharma, Chromocell Therapeutics, Argo Therapeutics, Foresite Labs, Exicure, Latigo Labs, Envida Biopharma, Ionis, Alnylam, Neurona Therapeutics, Shape Therapeutics, NxGen, Kineta Research, Arrowhead Therapeutics, Jazz Pharmaceuticals and Voyager Therapeutics. The other authors declare no competing interests.
